{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:45:02Z","timestamp":1792118702120,"version":"4.4.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Mirtazapine is used to treat depression worldwide, and the effects of mirtazapine on depression rating scales are well-known. Our primary objective was to assess the risks of adverse events with mirtazapine for major depressive disorder.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We searched relevant sources from inception to 7 March 2024 for randomised clinical trials comparing mirtazapine versus placebo in adults with major depressive disorder. The primary outcomes were suicides or suicide attempts, serious adverse events, and non-serious adverse events. Data were synthesised using meta-analysis and Trial Sequential Analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We included 17 trials randomising 2,131 participants to mirtazapine versus placebo. All results were at high risk of bias, and the certainty of the evidence was very low. The included trials assessed outcomes at a maximum of 12 weeks after randomisation. Meta-analysis and Trial Sequential Analysis showed insufficient information to determine the effects of mirtazapine on the risks of suicides or suicide attempts and serious adverse events. Meta-analyses showed that mirtazapine increased the risks of somnolence, weight gain, dry mouth, dizziness, and increased appetite but decreased the risk of headaches.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>There is a lack of evidence on the effects of mirtazapine on suicides and serious adverse events. Mirtazapine increases the risks of somnolence, weight gain, dry mouth, dizziness, and increased appetite. Mirtazapine might decrease the risk of headaches. The long-term effects of mirtazapine are unknown.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Prospero id<\/jats:title>\n            <jats:p>CRD42022315395.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12888-024-06396-6","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T14:55:52Z","timestamp":1737557752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The risks of adverse events with mirtazapine for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Caroline Barkholt","family":"Kamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne Juul","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Faltermeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Juul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Dam Bjerregaard","family":"Sillassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Kjaer","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Moncrieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Abie","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Pascal","family":"Hengartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janus Christian","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"issue":"10","key":"6396_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/0006-3223(95)00295-2","volume":"39","author":"Y-W Chen","year":"1996","unstructured":"Chen Y-W, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other axis I disorders. Biol Psychiatry. 1996;39(10):896\u20139.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"6396_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/acps.12301","volume":"131","author":"WW IsHak","year":"2015","unstructured":"IsHak WW, Mirocha J, James D, Tobia G, Vilhauer J, Fakhry H, et al. Quality of life in major depressive disorder before\/after multiple steps of treatment and one-year follow-up. Acta Psychiatrica Scandinavica. 2015;131(1):51\u201360.","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"6396_CR3","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2147\/NDT.S159276","volume":"14","author":"D Saragoussi","year":"2018","unstructured":"Saragoussi D, Christensen MC, Hammer-Helmich L, Rive B, Touya M, Haro JM. Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study. Neuropsychiatr Dis Treat. 2018;14:1339\u201350.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"7","key":"6396_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archpsyc.56.7.617","volume":"56","author":"RC Kessler","year":"1999","unstructured":"Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry. 1999;56(7):617\u201326.","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"6396_CR5","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jpsychires.2011.06.002","volume":"45","author":"P Qin","year":"2011","unstructured":"Qin P. The impact of psychiatric illness on suicide: differences by diagnosis of disorders and by sex and age of subjects. J Psychiatr Res. 2011;45(11):1445\u201352.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"6396_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1017\/S1092852918001207","volume":"24","author":"Z Pan","year":"2019","unstructured":"Pan Z, Park C, Brietzke E, Zuckerman H, Rong C, Mansur RB, et al. Cognitive impairment in major depressive disorder. CNS Spectr. 2019;24(1):22\u20139.","journal-title":"CNS Spectr"},{"key":"6396_CR7","unstructured":"World Health Organization. Depressive disorder (depression)2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression. [Accessed 1 September, 2024]."},{"issue":"3","key":"6396_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","volume":"7","author":"SA Anttila","year":"2001","unstructured":"Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249\u201364.","journal-title":"CNS Drug Rev"},{"issue":"5","key":"6396_CR9","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s00210-023-02818-6","volume":"397","author":"EHM Hassanein","year":"2024","unstructured":"Hassanein EHM, Althagafy HS, Baraka MA, Abd-alhameed EK, Ibrahim IM. Pharmacological update of mirtazapine: a narrative literature review. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(5):2603\u201319.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"6396_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0165-0327(98)00224-9","volume":"51","author":"J Fawcett","year":"1998","unstructured":"Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 1998;51(3):267\u201385.","journal-title":"J Affect Disord"},{"key":"6396_CR11","unstructured":"National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. https:\/\/www.nice.org.uk\/guidance\/ng222\/; 2022. [Accessed 1 September, 2024]."},{"key":"6396_CR12","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jad.2020.01.149","volume":"266","author":"H Sakurai","year":"2020","unstructured":"Sakurai H, Uchida H, Kato M, Suzuki T, Baba H, Watanabe K, et al. Pharmacological management of depression: Japanese expert consensus. J Affect Disord. 2020;266:626\u201332.","journal-title":"J Affect Disord"},{"issue":"9","key":"6396_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/07067437241245384","volume":"69","author":"RW Lam","year":"2024","unstructured":"Lam RW, Kennedy SH, Adams C, Bahji A, Beaulieu S, Bhat V, et al. Canadian Network for Mood and anxiety treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults: Reseau canadien pour les traitements de l\u2019humeur et de l\u2019anxiete (CANMAT) 2023: mise a jour des lignes directrices cliniques pour la prise en charge Du trouble depressif majeur chez les adultes. Can J Psychiatry. 2024;69(9):641\u201387.","journal-title":"Can J Psychiatry"},{"issue":"1","key":"6396_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/0004867420979353","volume":"55","author":"GS Malhi","year":"2021","unstructured":"Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2021;55(1):7\u2013117.","journal-title":"Aust N Z J Psychiatry"},{"key":"6396_CR15","unstructured":"National Health Service. Mirtazapine. https:\/\/www.nhs.uk\/medicines\/mirtazapine\/ Accessed 27 September 2022. https:\/\/www.nhs.uk\/medicines\/mirtazapine\/; 2019. [Accessed 27 September, 2022]."},{"key":"6396_CR16","unstructured":"European Medicines Agency. List of nationally authorised medicinal products. 2019."},{"key":"6396_CR17","unstructured":"U.S. Food & Drug Administration. Remeron (mirtazapine) Tablets. 2009."},{"key":"6396_CR18","unstructured":"EMA, Mirtazapine. List of nationally authorised medicinal products - PSUSA\/00002068\/202308. European Medicines Agency; 2024. Report No.: EMA\/177093\/2024."},{"key":"6396_CR19","unstructured":"Drugs@FDA FDA-A, Drug. Search Results for mirtazapine [Internet]. U.S. Food & Drug Administration. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process"},{"issue":"4","key":"6396_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/bmjebm-2019-111238","volume":"25","author":"JC Jakobsen","year":"2020","unstructured":"Jakobsen JC, Gluud C, Kirsch I. Should antidepressants be used for major depressive disorder? BMJ Evid Based Med. 2020;25(4):130.","journal-title":"BMJ Evid Based Med"},{"issue":"2","key":"6396_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/bmjebm-2020-111600","volume":"27","author":"MP Hengartner","year":"2022","unstructured":"Hengartner MP, Ploderl M. Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ Evid Based Med. 2022;27(2):69\u201373.","journal-title":"BMJ Evid Based Med"},{"issue":"10128","key":"6396_CR22","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357\u201366.","journal-title":"Lancet"},{"key":"6396_CR23","doi-asserted-by":"publisher","unstructured":"Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011: https:\/\/doi.org\/10.1002\/14651858.CD006528.pub2","DOI":"10.1002\/14651858.CD006528.pub2"},{"issue":"8","key":"6396_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/0269881107083808","volume":"22","author":"GI Papakostas","year":"2008","unstructured":"Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol. 2008;22(8):843\u20138.","journal-title":"J Psychopharmacol"},{"issue":"9","key":"6396_CR25","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.4088\/JCP.v69n0908","volume":"69","author":"N Watanabe","year":"2008","unstructured":"Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, et al. Mirtazapine Versus Other antidepressants in the Acute-Phase treatment of adults with Major Depression. J Clin Psychiatry. 2008;69(9):1404\u201315.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"6396_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4088\/JCP.v59n0306","volume":"59","author":"J Fawcett","year":"1998","unstructured":"Fawcett J, Barkin RL. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry. 1998;59(3):123\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"6396_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","volume":"6","author":"TA Furukawa","year":"2019","unstructured":"Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6(7):601\u20139.","journal-title":"Lancet Psychiatry"},{"issue":"Suppl 4","key":"6396_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00004850-199512004-00005","volume":"10","author":"S Kasper","year":"1995","unstructured":"Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol. 1995;10(Suppl 4):25\u201335.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"6396_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/11319480-000000000-00000","volume":"24","author":"N Watanabe","year":"2010","unstructured":"Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs. 2010;24(1):35\u201353.","journal-title":"CNS Drugs"},{"key":"6396_CR30","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M et al. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane, 2023. www.training.cochrane.org\/handbook; 2023."},{"issue":"1","key":"6396_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13643-023-02221-5","volume":"12","author":"CK Jorgensen","year":"2023","unstructured":"Jorgensen CK, Juul S, Siddiqui F, Horowitz MA, Moncrieff J, Munkholm K, et al. The risks of adverse events with venlafaxine and mirtazapine versus \u2018active placebo\u2019, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis. Syst Rev. 2023;12(1):57.","journal-title":"Syst Rev"},{"issue":"1","key":"6396_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.","journal-title":"Syst Rev"},{"key":"6396_CR33","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"issue":"1","key":"6396_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s13643-021-01789-0","volume":"10","author":"CK Jorgensen","year":"2021","unstructured":"Jorgensen CK, Juul S, Siddiqui F, Barbateskovic M, Munkholm K, Hengartner MP, et al. Tricyclic antidepressants versus \u2018active placebo\u2019, placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. Syst Reviews. 2021;10(1):227.","journal-title":"Syst Reviews"},{"key":"6396_CR35","doi-asserted-by":"crossref","unstructured":"Kamp CB, Petersen JJ, Faltermeier P, Juul S, Siddiqui F, Barbateskovic M et al. Beneficial and harmful effects of tricyclic antidepressants for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis. BMJ Mental Health. 2024;27(1).","DOI":"10.1136\/bmjment-2023-300730"},{"issue":"1","key":"6396_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13643-021-01722-5","volume":"10","author":"F Siddiqui","year":"2021","unstructured":"Siddiqui F, Barbateskovic M, Juul S, Katakam KK, Munkholm K, Gluud C, et al. Duloxetine versus \u2018active\u2019 placebo, placebo or no intervention for major depressive disorder; a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Syst Reviews. 2021;10(1):171.","journal-title":"Syst Reviews"},{"issue":"1","key":"6396_CR37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13643-021-01705-6","volume":"10","author":"S Juul","year":"2021","unstructured":"Juul S, Siddiqui F, Barbateskovic M, Jorgensen CK, Hengartner MP, Kirsch I, et al. Beneficial and harmful effects of antidepressants versus placebo, \u2018active placebo\u2019, or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses. Syst Reviews. 2021;10(1):154.","journal-title":"Syst Reviews"},{"key":"6396_CR38","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1017\/S2045796024000520","volume":"33","author":"CB Kamp","year":"2024","unstructured":"Kamp CB, Petersen JJ, Faltermeier P, Juul S, Siddiqui F, Moncrieff J, et al. The risks of adverse events with venlafaxine for adults with major depressive disorder: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis. Epidemiol Psychiatr Sci. 2024;33:e51.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"6396_CR39","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-5\u00ae)","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5\u00ae). Washington DC: American Psychiatric Publishing; 2013."},{"key":"6396_CR40","unstructured":"World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD). https:\/\/www.who.int\/standards\/classifications\/classification-of-diseases; 2021. [Accessed."},{"key":"6396_CR41","doi-asserted-by":"crossref","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). www.training.cochrane.org\/handbook; 2019. [Accessed September 1, 2020].","DOI":"10.1002\/9781119536604"},{"key":"6396_CR42","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"6396_CR43","unstructured":"International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised guideline: integrated addendum to ICH E6(R1): guideline for good clinical practice (ICH-GCP)2015; Step 2 version. https:\/\/ichgcp.net\/da. [Accessed September 1, 2020]."},{"issue":"4","key":"6396_CR44","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, \u00c5sberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382\u20139.","journal-title":"Br J Psychiatry"},{"key":"6396_CR45","first-page":"490","volume-title":"Beck depression inventory-II","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Brown GK. Beck depression inventory-II. San Antonio, TX: Psychological Corporation; 1996. pp. 490\u20138."},{"issue":"3","key":"6396_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000457131","volume":"86","author":"N Timmerby","year":"2017","unstructured":"Timmerby N, Andersen JH, S\u00f8ndergaard S, \u00d8stergaard SD, Bech P. A systematic review of the clinimetric properties of the 6-item version of the Hamilton Depression Rating Scale (HAM-D6). Psychother Psychosom. 2017;86(3):141\u20139.","journal-title":"Psychother Psychosom"},{"issue":"1","key":"6396_CR47","first-page":"143","volume":"9","author":"JA L\u00f3pez-Pina","year":"2009","unstructured":"L\u00f3pez-Pina JA, S\u00e1nchez-Meca J, Rosa-Alc\u00e1zar AI. The Hamilton Rating Scale for Depression: a meta-analytic reliability generalization study. Int J Clin Health Psychol. 2009;9(1):143\u201359.","journal-title":"Int J Clin Health Psychol"},{"issue":"1","key":"6396_CR48","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1471-2288-10-90","volume":"10","author":"F Keus","year":"2010","unstructured":"Keus F, Wetterslev J, Gluud C, van Laarhoven CJ. Evidence at a glance: error matrix approach for overviewing available evidence. BMC Med Res Methodol. 2010;10(1):90.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"6396_CR49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2288-14-120","volume":"14","author":"JC Jakobsen","year":"2014","unstructured":"Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol. 2014;14(1):120.","journal-title":"BMC Med Res Methodol"},{"key":"6396_CR50","unstructured":"StataCorp. Stata Statistical Software: Release 16 College Station, TX: StataCorp LLC. 2019. [Accessed September 1, 2020]."},{"issue":"1","key":"6396_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14(1):25.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"6396_CR52","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/sim.4780060325","volume":"6","author":"DL DeMets","year":"1987","unstructured":"DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med. 1987;6(3):341\u20138.","journal-title":"Stat Med"},{"key":"6396_CR53","unstructured":"Copenhagen Trial Unit - Centre for Clinical Intervention Research. TSA - Trial Sequential Analysis 0.9.5.10 Beta [Computer program]. Copenhagen Trial Unit, Centre for Clinical Intervention Research 2023. http:\/\/www.ctu.dk\/tsa\/. Accessed 26 Apr 2023 [Web page]. http:\/\/www.ctu.dk\/tsa\/; 2023. [Accessed September 1, 2020]."},{"issue":"1","key":"6396_CR54","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","volume":"61","author":"J Wetterslev","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61(1):64\u201375.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"6396_CR55","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","volume":"61","author":"J Brok","year":"2008","unstructured":"Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. 2008;61(8):763\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"6396_CR56","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/ije\/dyn188","volume":"38","author":"J Brok","year":"2008","unstructured":"Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive\u2014trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol. 2008;38(1):287\u201398.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"6396_CR57","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/ije\/dyn179","volume":"38","author":"K Thorlund","year":"2008","unstructured":"Thorlund K, Devereaux P, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol. 2008;38(1):276\u201386.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"6396_CR58","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2288-9-86","volume":"9","author":"J Wetterslev","year":"2009","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol. 2009;9(1):86.","journal-title":"BMC Med Res Methodol"},{"key":"6396_CR59","unstructured":"Thorlund K, Engstr\u00f8m J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA) Copenhagen, Denmark: Copenhagen Trial Unit, Centre for Clinical Intervention Research. http:\/\/www.ctu.dk\/tsa\/files\/tsa_manual.pdf; 2017. [Accessed September 1, 2020]."},{"key":"6396_CR60","first-page":"57","volume":"2","author":"K Thorlund","year":"2010","unstructured":"Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. J Clin Epidemiol. 2010;2:57.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"6396_CR61","doi-asserted-by":"publisher","first-page":"e011890","DOI":"10.1136\/bmjopen-2016-011890","volume":"6","author":"G Imberger","year":"2016","unstructured":"Imberger G, Thorlund K, Gluud C, Wetterslev J. False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review. BMJ Open. 2016;6(8):e011890.","journal-title":"BMJ Open"},{"issue":"4","key":"6396_CR62","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sch\u00fcnemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380\u20132.","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"6396_CR63","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Res ed). 2008;336(7650):924\u20136.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"7","key":"6396_CR64","first-page":"677","volume":"169","author":"HJ Sch\u00fcnemann","year":"2003","unstructured":"Sch\u00fcnemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. Can Med Assoc J. 2003;169(7):677\u201380.","journal-title":"Can Med Assoc J"},{"issue":"2","key":"6396_CR65","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00004714-199604000-00003","volume":"16","author":"JL Claghorn","year":"1996","unstructured":"Claghorn JL, Earl CQ, Walczak DD, Stoner KA, Wong LF, Kanter D, et al. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol. 1996;16(2):113\u201320.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"6396_CR66","first-page":"519","volume":"56","author":"JD Bremner","year":"1995","unstructured":"Bremner JD. A double-blind comparison of Org 3770, Amitriptyline, and placebo in major depression. J Clin Psychiatry. 1995;56(11):519\u201325.","journal-title":"J Clin Psychiatry"},{"key":"6396_CR67","first-page":"533","volume":"15","author":"JD Bremner","year":"1996","unstructured":"Bremner JD. Doppelblindvergleich Von Mirtazapin, Amitriptylin Und Plazebo Bei \u00bbMajor Depression\u00ab. Nervenheilkunde. 1996;15:533\u201340.","journal-title":"Nervenheilkunde"},{"key":"6396_CR68","unstructured":"Organon Scientific Development Group. Clinical Summary Report, Protocol 003\u2013022. A controlled study of Org 3770 in outpatients with major depression. 1990 (unpublished data)."},{"issue":"3","key":"6396_CR69","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1176\/appi.ajp.2009.09020186","volume":"167","author":"P Blier","year":"2010","unstructured":"Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281\u20138.","journal-title":"Am J Psychiatry"},{"issue":"S2","key":"6396_CR70","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1002\/hup.470100807","volume":"10","author":"JA Halikas","year":"1995","unstructured":"Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacology: Clin Experimental. 1995;10(S2):S125\u201333.","journal-title":"Hum Psychopharmacology: Clin Experimental"},{"issue":"2","key":"6396_CR71","first-page":"191","volume":"26","author":"WT Smith","year":"1990","unstructured":"Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. Amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull. 1990;26(2):191\u20136.","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"6396_CR72","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0924-977X(94)90008-6","volume":"4","author":"H Vartiainen","year":"1994","unstructured":"Vartiainen H, Leinonen E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol. 1994;4(2):145\u201350.","journal-title":"Eur Neuropsychopharmacol"},{"key":"6396_CR73","first-page":"289","volume":"12","author":"T Kinoshita","year":"2009","unstructured":"Kinoshita T. Double-blind placebo controlled study of mirtazapine, a novel antidepressant, in Japanese patients with depression or depressive state. Jpn J Clin Psychopharmacol. 2009;12:289\u2013306.","journal-title":"Jpn J Clin Psychopharmacol"},{"issue":"9","key":"6396_CR74","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/jcph.710","volume":"56","author":"K Funaki","year":"2016","unstructured":"Funaki K, Nakajima S, Suzuki T, Mimura M, Uchida H. Early improvements in individual symptoms to Predict later remission in major depressive disorder treated with Mirtazapine. J Clin Pharmacol. 2016;56(9):1111\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"6396_CR75","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/ebmental-2018-300073","volume":"22","author":"K Shinohara","year":"2019","unstructured":"Shinohara K, Tanaka S, Imai H, Noma H, Maruo K, Cipriani A, et al. Development and validation of a prediction model for the probability of responding to placebo in antidepressant trials: a pooled analysis of individual patient data. Evid Based Ment Health. 2019;22(1):10\u20136.","journal-title":"Evid Based Ment Health"},{"key":"6396_CR76","doi-asserted-by":"crossref","unstructured":"Jacobson AF. 1990. In: Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol. 2001;4(4):337\u2009\u2013\u200945.","DOI":"10.1017\/S1461145701002565"},{"key":"6396_CR77","first-page":"CD009138","volume":"12","author":"C Leucht","year":"2012","unstructured":"Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev. 2012;12:CD009138.","journal-title":"Cochrane Database Syst Rev"},{"key":"6396_CR78","unstructured":"Organon. 3\u2013020. In: Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol. 2001;4(4):337\u2009\u2013\u200945."},{"key":"6396_CR79","doi-asserted-by":"crossref","unstructured":"Organon UK. unpublished. In: Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol. 2001;4(4):337\u2009\u2013\u200945.","DOI":"10.1017\/S1461145701002565"},{"issue":"S2","key":"6396_CR80","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1002\/hup.470100806","volume":"10","author":"MC Khan","year":"1995","unstructured":"Khan MC. A randomised, double-blind, placebo-controlled, 5-weeks\u2019 study of org 3770 (mirtazapine) in major depression. Hum Psychopharmacology: Clin Experimental. 1995;10(S2):S119\u201324.","journal-title":"Hum Psychopharmacology: Clin Experimental"},{"key":"6396_CR81","unstructured":"Organon Scientific Development Group. A double-blind, placebo-controlled, flexible dose efficacy and safety study with Org 3770 administered orally for a period of five weeks to patients with major depressive episode (multicentre study). 1991 (unpublished data)."},{"issue":"7","key":"6396_CR82","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1017\/S0033291719004069","volume":"51","author":"L Xiao","year":"2021","unstructured":"Xiao L, Zhu X, Gillespie A, Feng Y, Zhou J, Chen X, et al. Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial. Psychol Med. 2021;51(7):1166\u201374.","journal-title":"Psychol Med"},{"issue":"2","key":"6396_CR83","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0006-3223(01)01262-8","volume":"51","author":"LL Carpenter","year":"2002","unstructured":"Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51(2):183\u20138.","journal-title":"Biol Psychiatry"},{"key":"6396_CR84","doi-asserted-by":"publisher","first-page":"k4218","DOI":"10.1136\/bmj.k4218","volume":"363","author":"DS Kessler","year":"2018","unstructured":"Kessler DS, MacNeill SJ, Tallon D, Lewis G, Peters TJ, Hollingworth W, et al. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). BMJ. 2018;363:k4218.","journal-title":"BMJ"},{"issue":"63","key":"6396_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22630","volume":"22","author":"D Kessler","year":"2018","unstructured":"Kessler D, Burns A, Tallon D, Lewis G, MacNeill S, Round J, et al. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. Health Technol Assess. 2018;22(63):1\u2013136.","journal-title":"Health Technol Assess"},{"key":"6396_CR86","doi-asserted-by":"crossref","unstructured":"Rao IM, Prayaga UK, Uppada DR, Rao ER, Kudagi BL. A double-blind randomized placebo-controlled study of low dose mirtazapine once daily in patients of major depressive disorders on escitalopram. Int J Basic Clin Pharmacol. 2019;8(5).","DOI":"10.18203\/2319-2003.ijbcp20191602"},{"key":"6396_CR87","unstructured":"Organon Scientific Development Group. A double-blind, placebo-controlled efficacy and safety study with Org 3770 (15, 30 and 60\u00a0mg daily) administered orally for a period of 5 weeks to patients suffering from major depression. (Dr Elkes). 1989 (unpublished data)."},{"key":"6396_CR88","unstructured":"U.S. Food & Drug Administration. 003\u2013003. In: NDA 20\u2013415. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/96\/020415Orig1s000rev.pdf; 1996. [Accessed 1 October, 2024]."},{"key":"6396_CR89","unstructured":"U.S. Food & Drug Administration. 003\u2013008. In: NDA 20\u2013415. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/96\/020415Orig1s000rev.pdf;;1996. [Accessed 1 October, 2024]."},{"key":"6396_CR90","unstructured":"U.S. Food & Drug Administration. 84023. In: NDA 20\u2013415. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/96\/020415Orig1s000rev.pdf;;1996. [Accessed."},{"issue":"3","key":"6396_CR91","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/bmjebm-2020-111407","volume":"26","author":"S Juul","year":"2021","unstructured":"Juul S, Gluud C, Simonsen S, Frandsen FW, Kirsch I, Jakobsen JC. Blinding in randomised clinical trials of psychological interventions: a retrospective study of published trial reports. BMJ Evid Based Med. 2021;26(3):109.","journal-title":"BMJ Evid Based Med"},{"issue":"5","key":"6396_CR92","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/00001648-199209000-00009","volume":"3","author":"DR Ragland","year":"1992","unstructured":"Ragland DR. Dichotomizing continuous outcome variables: dependence of the magnitude of association and statistical power on the cutpoint. Epidemiol. 1992;3(5):434\u201340.","journal-title":"Epidemiol"},{"issue":"2","key":"6396_CR93","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/0272989X12437605","volume":"32","author":"NV Dawson","year":"2012","unstructured":"Dawson NV, Weiss R. Dichotomizing continuous variables in statistical analysis: a practice to avoid. Med Decis Mak. 2012;32(2):225\u20136.","journal-title":"Med Decis Mak"},{"issue":"7549","key":"6396_CR94","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","volume":"332","author":"DG Altman","year":"2006","unstructured":"Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332(7549):1080.","journal-title":"BMJ"},{"issue":"4","key":"6396_CR95","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.cct.2006.10.012","volume":"28","author":"I Kirsch","year":"2007","unstructured":"Kirsch I, Moncrieff J. Clinical trials and the response rate illusion. Contemp Clin Trials. 2007;28(4):348\u201351.","journal-title":"Contemp Clin Trials"},{"key":"6396_CR96","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M et al. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane, 2021. www.training.cochrane.org\/handbook; 2021."},{"issue":"9","key":"6396_CR97","doi-asserted-by":"publisher","first-page":"e1002127","DOI":"10.1371\/journal.pmed.1002127","volume":"13","author":"S Golder","year":"2016","unstructured":"Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished studies of Health Care interventions: a systematic review. PLoS Med. 2016;13(9):e1002127.","journal-title":"PLoS Med"},{"key":"6396_CR98","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12916-015-0430-4","volume":"13","author":"E Tang","year":"2015","unstructured":"Tang E, Ravaud P, Riveros C, Perrodeau E, Dechartres A. Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles. BMC Med. 2015;13:189.","journal-title":"BMC Med"},{"key":"6396_CR99","doi-asserted-by":"crossref","unstructured":"Maund E, Tendal B, Hr\u00f3bjartsson A, J\u00f8rgensen KJ, Lundh A, Schroll J et al. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ. 2014;348.","DOI":"10.1136\/bmj.g3510"},{"issue":"604","key":"6396_CR100","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.3399\/bjgp12X658304","volume":"62","author":"CF Johnson","year":"2012","unstructured":"Johnson CF, Macdonald HJ, Atkinson P, Buchanan AI, Downes N, Dougall N. Reviewing long-term antidepressants can reduce drug burden: a prospective observational cohort study. Br J Gen Pract. 2012;62(604):e773\u20139.","journal-title":"Br J Gen Pract"},{"issue":"2","key":"6396_CR101","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4088\/JCP.13m08443","volume":"75","author":"R Mojtabai","year":"2014","unstructured":"Mojtabai R, Olfson M. National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey. J Clin Psychiatry. 2014;75(2):169\u201377.","journal-title":"J Clin Psychiatry"},{"key":"6396_CR102","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jad.2018.10.357","volume":"245","author":"G Kinrys","year":"2019","unstructured":"Kinrys G, Gold AK, Pisano VD, Freeman MP, Papakostas GI, Mischoulon D, et al. Tachyphylaxis in major depressive disorder: a review of the current state of research. J Affect Disord. 2019;245:488\u201397.","journal-title":"J Affect Disord"},{"issue":"5","key":"6396_CR103","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/aje\/kwx344","volume":"187","author":"J Savovic","year":"2018","unstructured":"Savovic J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JPT, et al. Association between Risk-of-Bias assessments and results of randomized trials in Cochrane Reviews: the ROBES Meta-epidemiologic study. Am J Epidemiol. 2018;187(5):1113\u201322.","journal-title":"Am J Epidemiol"},{"issue":"7644","key":"6396_CR104","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","volume":"336","author":"L Wood","year":"2008","unstructured":"Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336(7644):601\u20135.","journal-title":"BMJ"},{"issue":"6","key":"6396_CR105","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/aje\/kwj069","volume":"163","author":"LL Gluud","year":"2006","unstructured":"Gluud LL. Bias in clinical intervention research. Am J Epidemiol. 2006;163(6):493\u2013501.","journal-title":"Am J Epidemiol"},{"issue":"11","key":"6396_CR106","doi-asserted-by":"publisher","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","volume":"135","author":"LL Kjaergard","year":"2001","unstructured":"Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001;135(11):982\u20139.","journal-title":"Ann Intern Med"},{"issue":"7303","key":"6396_CR107","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","volume":"323","author":"P J\u00fcni","year":"2001","unstructured":"J\u00fcni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ. 2001;323(7303):42\u20136.","journal-title":"BMJ"},{"issue":"9128","key":"6396_CR108","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","volume":"352","author":"D Moher","year":"1998","unstructured":"Moher D, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609\u201313.","journal-title":"Lancet"},{"issue":"5","key":"6396_CR109","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","volume":"273","author":"KF Schulz","year":"1995","unstructured":"Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408\u201312.","journal-title":"JAMA"},{"issue":"4","key":"6396_CR110","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/ije\/dyu115","volume":"43","author":"A Hrobjartsson","year":"2014","unstructured":"Hrobjartsson A, Emanuelsson F, Skou Thomsen AS, Hilden J, Brorson S. Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. Int J Epidemiol. 2014;43(4):1272\u201383.","journal-title":"Int J Epidemiol"},{"key":"6396_CR111","doi-asserted-by":"crossref","unstructured":"Hrobjartsson A, Skou Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. CMAJ. 2013;185(4).","DOI":"10.1503\/cmaj.120744"},{"key":"6396_CR112","doi-asserted-by":"publisher","first-page":"e1119","DOI":"10.1136\/bmj.e1119","volume":"344","author":"A Hrobjartsson","year":"2012","unstructured":"Hrobjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ. 2012;344:e1119.","journal-title":"BMJ"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06396-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-06396-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06396-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T14:56:09Z","timestamp":1737557769000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-06396-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6396"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-06396-6","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"8 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We received no support from any organisation for the submitted work. MAH and JM are a co-applicants of the RELEASE and RELEASE+ trials in Australia, funded by the Medical Research Future Fund (MRFF) and the National Health and Medical Research Council (NHMRC). MAH receives royalties from Wiley Blackwell for the Maudsley Deprescribing Guidelines. MAH is co-founder and consultant for Outro Health, a digital clinic aiming to help patients to stop unnecessary antidepressant medication. MAH has been paid honoraria by several NHS Trusts for grand rounds presentations, and by Salomon\u2019s University, the University of Arizona, and the University of Washington. JM is a co-investigator on REDUCE (programme grant studying discontinuation of antidepressants) and Chief Investigator on RADAR (programme grant to explore antipsychotic reduction and discontinuation). JM has been paid honoraria by University of Basel, Alberta Psychiatric Association, and Case Western University. JM receives royalties from Palgrave Macmillan and PCCS Books for three books about psychiatric drugs. JM is a co-chair person (unfunded position) of Critical Psychiatry Network. MPH receives royalties from Palgrave Macmillan for a book about antidepressants. We report no other relationships or activities that could appear to have influenced the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"67"}}